Lucid Diagnostics (NASDAQ:LUCD) Raised to Strong-Buy at Canaccord Genuity Group

Canaccord Genuity Group upgraded shares of Lucid Diagnostics (NASDAQ:LUCD) to a strong-buy rating in a research note published on Tuesday morning, Zacks.com reports.

A number of other equities analysts have also recently weighed in on LUCD. Canaccord Genuity Group reissued a buy rating and set a $3.00 price target on shares of Lucid Diagnostics in a research report on Tuesday. Cantor Fitzgerald reissued an overweight rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research note on Wednesday, May 15th. Needham & Company LLC reaffirmed a buy rating and set a $2.50 price target on shares of Lucid Diagnostics in a research report on Tuesday. Finally, Ascendiant Capital Markets cut their price objective on Lucid Diagnostics from $8.00 to $7.50 and set a buy rating on the stock in a report on Thursday, June 6th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Buy and a consensus price target of $4.00.

Lucid Diagnostics Price Performance

Shares of NASDAQ:LUCD traded up $0.00 during trading on Tuesday, reaching $0.84. The stock had a trading volume of 10,847 shares, compared to its average volume of 155,845. The stock has a market capitalization of $43.77 million, a PE ratio of -0.66 and a beta of 1.45. Lucid Diagnostics has a 52 week low of $0.63 and a 52 week high of $1.72. The business’s 50-day moving average price is $0.80 and its 200 day moving average price is $0.96.

Lucid Diagnostics (NASDAQ:LUCD) last released its earnings results on Monday, May 13th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $1.00 million during the quarter. Analysts forecast that Lucid Diagnostics will post -1.06 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lucid Diagnostics stock. Virtu Financial LLC lifted its holdings in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,671 shares of the company’s stock after purchasing an additional 13,835 shares during the quarter. Virtu Financial LLC owned 0.07% of Lucid Diagnostics worth $28,000 as of its most recent SEC filing. Institutional investors and hedge funds own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.